未登录 分享 收藏
分享 收藏
Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy Ebinc, Senar; Oruc, Zeynep; Sezgin, Yasin; Karhan, Ogur; Bilen, Erkan; Yerlikaya, Halis; Kalkan, Ziya; Urakci, Zuhat; Kucukoner, Mehmet; Kaplan, Muhammet Ali; Isikdogan, Abdurrahman 分享 收藏
First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis Isikdogan, A.; Turk, H.; Bilir, C.; Sendur, M.; Karabulut, B.; Artac, M.; Cicin, I.; Geredeli, C.; Alacacioglu, A.; Kefeli, U.; Harputluoglu, H.; Bozkurt, O.; Cubukcu, E.; Tural, D.; Sakin, A.; Cil, T.; Dane, F.; Cevik, D.; Arslan, C.; Karadurmus, N.; Gumus, M.; Yalcin, S. 分享 收藏
Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study 新型冠状病毒肺炎疫苗在癌症患者中的有效性和安全性: 一项前瞻性多中心队列研究 Yasin, Ayse Irem; Aydin, Sabin Goktas; Sumbul, Bilge; Koral, Lokman; Simsek, Melih; Geredeli, Caglayan; Ozturk, Akin; Perkin, Perihan; Demirtas, Derya; Erdemoglu, Engin; Hacibekiroglu, Ilhan; Cakir, Emre; Tanrikulu, Eda; Coban, Ezgi; Ozcelik, Melike; Celik, Sinemis; Teker, Fatih; Aksoy, Asude; Firat, Sedat T.; Tekin, Omer; Kalkan, Ziya; Turken, Orhan; Oven, Bala B.; Dane, Faysal; Bilici, Ahmet; Isikdogan, Abdurrahman; Seker, Mesut; Turk, Haci M.; Gumus, Mahmut 分享 收藏
Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study Arslan, C.; Kefeli, U.; Yildirim, E.; Isikdogan, A.; Karadurmus, N.; Karabulut, B.; Cicin, I.; Cubukcu, E.; Bilir, C.; Ozcelik, M.; Cil, T.; Celik, S.; Bozkurt, O.; Harputluoglu, H.; Oven, B.; Geredeli, C.; Tural, D.; Sakin, A.; Cevik, D.; Gumus, M.; Yalcin, S. 分享 收藏
Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases Oruc, Zeynep; Kaplan, M. Ali; Karaagac, Mustafa; Ozyurt, Neslihan; Tatli, Ali Murat; Kaya, Ali Osman; Menekse, Serkan; Kut, Engin; Koca, Sinan; Sever, Ozlem Nuray; Yasin, Irem; Ebinc, Senar; Zeynelgil, Esra; Sakin, Abdullah; Turhal, Nazim Serdar; Isikdogan, Abdurrahman 分享 收藏
Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine plus nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study Yalcin, Suayib; Dane, Faysal; Oksuzoglu, Berna; Ozdemir, Nuriye Yildirim; Isikdogan, Abdurrahman; Ozkan, Metin; Demirag, Guzin Gonullu; Coskun, Hasan Senol; Karabulut, Bulent; Evrensel, Turkkan; Ustaoglu, Mehmet Ali; Ozdemir, Feyyaz; Turna, Hande; Yavuzsen, Tugba; Aykan, Faruk; Sevinc, Alper; Akbulut, Hakan; Yuce, Deniz; Hayran, Mutlu; Kilickap, Saadettin 分享 收藏
Is lymph node ratio (LNR) having additional contribution for predict prognosis on pathologic lymph node staging in node -positive breast cancer patients? Kaplan, M. A.; Odabasi, H.; Ozdemir, N.; Harputluoglu, H.; Aliustaoglu, M.; Berk, V.; Gunaydin, Y.; Uncu, D.; Elkiran, T.; Aydin, D.; Isikdogan, A. 分享 收藏
分享 收藏
Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG) Icli, Fikri; Altundag, Kadri; Akbulut, Hakan; Paydas, Semra; Basaran, Gul; Saip, Pinar; Dogu, Gamze G.; Erlap, Yesim; Uslu, Ruchan; Sevinc, Alper; Onur, Handan; Mandel, Nil M.; Sezgin, Canfeza; Altinbas, Mustafa; Guler, Nilufer; Isikdogan, Abdurrahman; Gokmen, Erhan; Uygun, Kazim; Ustuner, Zeki; Yaren, Arzu; Demirkan, Binnaz; Coskun, Ugur; Ata, Alper; Ozkan, Metin; Arican, Ali 分享 收藏
Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial Saip, P.; Eralp, Y.; Sen, F.; Karaca, H.; Ozkan, M.; Cetin, B.; Benekli, M.; Kucukoner, M.; Isikdogan, A.; Un, O.; Basaran, G.; Onur, H. 分享 收藏
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology 接受拉帕替尼联合卡培他滨联合治疗的HER2-positive乳腺癌脑转移患者的临床结局以及与接受曲妥珠单抗治疗的患者的生存率比较: 安那托利亚医学肿瘤学会的一项研究 Kaplan, Muhammet Ali; Isikdogan, Abdurrahman; Koca, Dogan; Kucukoner, Mehmet; Gumusay, Ozge; Yildiz, Ramazan; Dayan, Adem; Demir, Lutfiye; Geredeli, Caglayan; Kocer, Murat; Arslan, Ulku Yalcintas; Inal, Ali; Akman, Tulay; Coskun, Ugur; Sener, Nur; Inanc, Mevlude; Elkiran, Emin Tamer; Ozdemir, Nuriye Yildirim; Durnali, Ayse Gok; Suner, Ali; Alici, Suleyman; Tarhan, Mustafa Oktay; Boruban, Cem; Oksuzoglu, Berna; Urakci, Zuhat 分享 收藏
Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study). Abulkhair, O.; Uslu, R.; Sezgin, C.; Bueyuekberber, S.; Darwish, T.; Isikdogan, A.; Gumus, M.; Dane, F.; Sevinc, A.; Halawani, H.; Uncu, D.; Marrero, N.; Tobler, J.; Soares, C.; Landis, S.; Moraes, E.; Gidekel, R.; Santillana, S.; Nunez, P.; Cagnolati, S.; Rodriguez, J. G. 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
BREAST CANCER.png)
.png){kind=icon}
分享.png){kind=icon}
收藏